Pyrimidines

Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease

Retrieved on: 
Monday, August 2, 2021

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) --  Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced the initiation of the APOLLO-CD Phase 2a clinical trial evaluating PRA023 for moderate-to-severe Crohn’s disease (CD), with first patient enrollment.  

Key Points: 
  • We believe PRA023 has the potential to address the highest unmet need of fibrostenotic disease in this patient population.
  • The APOLLO-CD Phase 2a trial is an open-label study designed to evaluate the proof-of-concept efficacy and safety of PRA023 in moderate-to-severe Crohns disease with centrally read endoscopy as the primary endpoint.
  • Prometheus has recently completed the dosing phase of the Phase 1a clinical trial of PRA023, a single center, double-blind, placebo-controlled trial to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRA023 in normal healthy volunteers.
  • Safety and tolerability observed to date supports the initiation of this Phase 2a trial.

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

Retrieved on: 
Saturday, July 17, 2021

Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.

Key Points: 
  • Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.
  • A corresponding trial in Europe, CARISEL, is examining the implementation of long-acting cabotegravir and rilpivirine, dosed every 2-months in certain European healthcare settings.
  • Marketing Authorisations for the long-acting regimen of cabotegravir and rilpivirine were granted by the European Medicines Agency in December 2020.
  • Sustainment of implementation strategies was assessed via surveys and semi-structured interviews of staff study participants as well as patient study participants.

2021 Global Trimethoprim (CAS 738-70-5) Market Research Report - Key Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021

The "Trimethoprim (CAS 738-70-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Trimethoprim (CAS 738-70-5) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Trimethoprim.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Trimethoprim global market report key points:

Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19

Retrieved on: 
Thursday, June 3, 2021

WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, announced today that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897 ).

Key Points: 
  • WAKEFIELD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, announced today that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897 ).
  • Innovation Pharmaceuticals is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation.
  • Complete trial enrollment comprised 120 dosed patients recruited across multiple sites.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.

Patient Enrollment Reaches 90 Percent in Innovation Pharmaceuticals Phase 2 Clinical Trial of Brilacidin for COVID-19

Retrieved on: 
Thursday, May 27, 2021

WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Companys 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks.

Key Points: 
  • WAKEFIELD, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (the Company), a clinical stage biopharmaceutical company, today announces that patient enrollment in the Companys 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 has reached 90 percent and that the Company anticipates full enrollment to be completed in approximately two weeks.
  • Innovation Pharma is developing Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients under U.S. FDA Fast Track designation (see NCT04784897 ).
  • The Company intends to provide an update to shareholders upon the final patients entering the trial.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.

NuCana to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 25, 2021

EDINBURGH, United Kingdom, May 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference being held from June 1 to June 4, 2021.

Key Points: 
  • EDINBURGH, United Kingdom, May 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference being held from June 1 to June 4, 2021.
  • Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
  • Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents.
  • Forward-looking statements represent the Companys beliefs and assumptions only as of the date of this press release.

Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic Hepatitis B Virus Patients on Treatment with a Nucleoside Reverse Transcriptase Inhibitor

Retrieved on: 
Thursday, May 6, 2021

Patients were randomized to receive 200 mg (n=6), 400 mg (n=6), 800 mg (n=6) of EDP-514 or placebo (n=6) daily for 28 days.

Key Points: 
  • Patients were randomized to receive 200 mg (n=6), 400 mg (n=6), 800 mg (n=6) of EDP-514 or placebo (n=6) daily for 28 days.
  • EDP-514 was safe and well-tolerated and pharmacokinetics were supportive of once daily dosing, consistent with what was observed in Part 1 in healthy subjects.
  • Six of 12 patients given EDP-514 had at least one grade 1 or 2 AE during treatment.
  • It is estimated that over 290 million people worldwide have chronic HBV infection.1 Current approaches to treatment include interferon therapy and/or NUCs.

NuCana to Participate in the 7th Annual Truist Securities Life Sciences Summit

Retrieved on: 
Wednesday, April 28, 2021

Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Key Points: 
  • Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
  • NuCana\xe2\x80\x99s robust pipeline includes three ProTides in clinical development.
  • Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents.
  • Forward-looking statements represent the Company\xe2\x80\x99s beliefs and assumptions only as of the date of this press release.

Investigational Combination of Aliqopa® (copanlisib) and rituximab Significantly Increases Progression-Free Survival in Patients with Relapsed Indolent non-Hodgkin's Lymphoma

Retrieved on: 
Saturday, April 10, 2021

The results reported with the combination of copanlisib and rituximab suggest a potential advancement for patients with these diverse types of cancers.

Key Points: 
  • The results reported with the combination of copanlisib and rituximab suggest a potential advancement for patients with these diverse types of cancers.
  • Of the relapsed iNHL patients included in the trial, 60% had FL, 20.7% marginal zone lymphoma (MZL), 10.9% small lymphocytic lymphoma (SLL) and 8.3% lymphoplasmacytoid lymphoma/Waldenstrm macroglobulinemia (LPL/WM).
  • Aliqopa (copanlisib) is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
  • Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.

Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients

Retrieved on: 
Monday, April 5, 2021

Upon reaching 25 percent enrollment (30 subjects), recruitment was paused and a pre-specified unblinded safety data review and evaluation was conducted by the DMC.

Key Points: 
  • Upon reaching 25 percent enrollment (30 subjects), recruitment was paused and a pre-specified unblinded safety data review and evaluation was conducted by the DMC.
  • Efficacy data was not reviewed by the DMC and remains blinded.
  • Trial data for Veklury could serve as a benchmark in evaluating Brilacidin outcomes.
  • Innovation Pharma is developing Brilacidin, a defensin-mimetic, under Fast Track designation from the U.S. Food and Drug Administration (FDA).